Annovis Bio, Inc. (ANVS) - Form 8-K Summary
Business Context and Reporting Period
Annovis Bio, Inc., a Delaware corporation, filed this Current Report on Form 8-K on March 16, 2026. The filing serves to announce the issuance of a press release detailing the company's earnings for the fiscal year ended December 31, 2025. The company is classified as an emerging growth company.
Key Financial Metrics
The provided filing text does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. The document acts as a notification that these results were released in a separate press release (Exhibit 99), which is incorporated by reference but not included in the source text provided.
Material Changes
No material changes versus the prior comparable period are detailed in this specific filing text. The document only confirms the reporting of the 2025 full-year results.
Guidance, Outlook, and Risks
The filing text does not provide management commentary, future guidance, specific risk factors, contingencies, or details on unusual items. These elements are contained within the referenced press release (Exhibit 99) rather than the 8-K cover document.
Investor Verification Checklist
- Verify the specific financial results (revenue, net loss, cash position) by reviewing the press release dated March 16, 2026, referenced as Exhibit 99.
- Confirm the company's cash runway and burn rate based on the full-year 2025 data.
- Review the press release for any updates on clinical trial progress or regulatory milestones for the company's drug candidates.
- Check for any new debt financing or equity raises disclosed in the full earnings release.